NASDAQ:PCRX - Pacira Biosciences Stock Price, Forecast & News

Pacira Biosciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PCRX stock has decreased by 9.8% and is now trading at $31.73. View which stocks have been mosted impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacira Biosciences.

Pacira Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Pacira Biosciences.

Pacira Biosciences Inc (NASDAQ:PCRX) posted its quarterly earnings results on Thursday, February, 20th. The company reported $0.56 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.21 by $0.35. The firm had revenue of $122.42 million for the quarter, compared to the consensus estimate of $122.04 million. Pacira Biosciences had a positive return on equity of 10.81% and a negative net margin of 2.62%. Pacira Biosciences's revenue was up 28.7% compared to the same quarter last year. During the same period last year, the firm posted $0.47 earnings per share. View Pacira Biosciences' earnings history.

Pacira Biosciences updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $485-500 million, compared to the consensus revenue estimate of $495.91 million.

15 analysts have issued 12-month price objectives for Pacira Biosciences' stock. Their forecasts range from $38.00 to $85.00. On average, they expect Pacira Biosciences' share price to reach $54.00 in the next year. This suggests a possible upside of 70.2% from the stock's current price. View analysts' price targets for Pacira Biosciences.

Press coverage about PCRX stock has trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pacira Biosciences earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutPacira Biosciences.

Pacira Biosciences saw a increase in short interest in February. As of February 14th, there was short interest totaling 4,450,000 shares, an increase of 7.0% from the January 30th total of 4,160,000 shares. Based on an average daily trading volume, of 481,900 shares, the short-interest ratio is currently 9.2 days. Currently, 11.0% of the company's shares are sold short. View Pacira Biosciences' Current Options Chain.

Some companies that are related to Pacira Biosciences include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Celgene (CELG), Clovis Oncology (CLVS), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Bausch Health Companies (BHC), Exelixis (EXEL) and Incyte (INCY).

Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX."

Pacira Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.31%), Baillie Gifford & Co. (3.32%), State Street Corp (3.19%), Schroder Investment Management Group (2.18%), Spyglass Capital Management LLC (2.05%) and Geode Capital Management LLC (1.53%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings, Richard Scranton and Roy Winston. View institutional ownership trends for Pacira Biosciences.

PCRX stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Nuveen Asset Management LLC, Point72 Asset Management L.P., Marshall Wace LLP, Tamarack Advisers LP, AQR Capital Management LLC, Maverick Capital Ltd., and First Trust Advisors LP. Company insiders that have sold Pacira Biosciences company stock in the last year include Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings, and Richard Scranton. View insider buying and selling activity for Pacira Biosciences.

PCRX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Norges Bank, Spyglass Capital Management LLC, Baillie Gifford & Co., Great Lakes Advisors LLC, Schroder Investment Management Group, California Public Employees Retirement System, and UBS Group AG. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace, Mark A Kronenfeld, and Roy Winston. View insider buying and selling activity for Pacira Biosciences.

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PCRX stock can currently be purchased for approximately $31.73.

Pacira Biosciences has a market capitalization of $1.33 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe. View additional information about Pacira Biosciences.

The official website for Pacira Biosciences is http://www.pacira.com/.

Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]